GILD34:BVMF
Gilead Sciences Inc BDR
R$ 65.81
0.00%
(0.00) Siku 1
16 Okt, 16:56:00 GMT -3 · BRL
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya GILD34...
Fungua
R$ 66.36
Juu
R$ 66.41
Chini
R$ 65.81
Mtaji wa soko
193.67B
Wastani wa kiasi cha mauzo
261.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
R$ 67.38
Chini kwa wiki 52
R$ 51.33
Hisa za wawekezaji
1.24B
Idadi ya wafanyakazi
elfu 17
Fungua
R$ 66.36
Juu
R$ 66.41
Chini
R$ 65.81
Mtaji wa soko
193.67B
Wastani wa kiasi cha mauzo
261.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
R$ 67.38
Chini kwa wiki 52
R$ 51.33
Hisa za wawekezaji
1.24B
Idadi ya wafanyakazi
elfu 17
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
ad-hoc-news.de
·
saa 2 zilizopita
Gilead Sciences stock sits 2.32 percent below its yearly high
ad-hoc-news.de
·
saa 4 zilizopita
Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher
The Motley Fool
·
saa 16 zilizopita
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
Simply Wall Street
·
siku 1 iliyopita
Did Cancer Drug Partnership Just Shift Gilead's (GILD) Investment Narrative?
Wasifu
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Kuhusu Gilead Sciences Inc BDR
Afisa Mkuu Mtendaji (CEO)Daniel O'Day
Wafanyakazielfu 17
Lilianzishwa22 Jun 1987
Makao makuuFoster City, California, Marekani
Sekta-
Tovutigilead.com